Dropouts due to adverse events · patients with the treatment of cocaine dependence
It is very uncertain whether summary of findings table – disulfiram changes dropout due to adverse events (number of participants who did not… compared with naltrexone (very low certainty).
1 finding from 1 review
RR 0.5 [0.07, 3.55]
1 study · 8 participants
Very low
Dropouts due to adverse events · patients with the treatment of cocaine dependence
It is very uncertain whether summary of findings table – disulfiram changes dropout due to adverse events (number of participants who did not… compared with placebo or no pharmacological treatment (very low certainty).
1 finding from 1 review
Secondary outcome: all adverse eventsOral · adult patients with the common cold
Summary of findings for multi‐dose nasal decongestant showed no clear difference in secondary outcome: all adverse eventsOral compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events ‐ not measured · older people in all long‐term care settings
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: all adverse eventsTopical · adult patients with the common cold
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
Summary of findings table ‐ Subcutaneous biologics (dupilumab) showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Rate of adverse events excluding falls (per person year) · people with Parkinson's disease
Summary of findings for cholinesterase inhibitors may leads to higher rate of adverse events excluding falls (per person year) compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ abdominal overdistention · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes adverse events ‐ abdominal overdistention compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Adverse events at study endpoint · preventing mental disorders
2 findings from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF
1 finding from 1 review
Treatment‐related adverse events Anxiety: GAD‐7 (Spitzer 2006) · children, adolescents or adults with CF
Summary of findings: psychological interventions showed no clear difference in treatment‐related adverse events Anxiety: GAD‐7 (Spitzer 2006) compared with usual care (low certainty).
1 finding from 1 review
Treatment‐related adverse events Depression PHQ‐8 (Kroenke 2009) · children, adolescents or adults with CF
Summary of findings: psychological interventions showed no clear difference in treatment‐related adverse events Depression PHQ‐8 (Kroenke 2009) compared with usual care (low certainty).
1 finding from 1 review
Short‐term serious adverse events (SAEs) · adults undergoing intra‐ and transperitoneal laparoscopic procedures
It is very uncertain whether summary of findings table ‐ Deep neuromuscular blockade (NMB) changes short‐term serious adverse events (SAEs) compared with moderate NMB (very low certainty).
1 finding from 1 review
Short‐term serious adverse events (SAEs) · adults undergoing intra‐ and transperitoneal laparoscopic procedures
It is very uncertain whether summary of findings table ‐ Deep neuromuscular blockade (NMB) changes short‐term serious adverse events (SAEs) compared with shallow NMB (very low certainty).
1 finding from 1 review
Number experiencing adverse effects · children (12 or over) and adults with cystic fibrosis and lung infection
It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes adverse events number of participants experiencing adverse events compared with placebo (very low certainty).
1 finding from 1 review
Adverse events (12 (12, 26)) · people with congenital heart disease.
1 finding from 1 review
Adverse events: number of any adverse event reported · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: tobramycin for inhalation powder showed no clear difference in adverse events: number of any adverse event reported compared with tobramycin (moderate certainty).
1 finding from 1 review
Adverse events: occurring in at least 10% of cavosonstat treated participants · adults and children with cystic fibrosis
1 finding from 1 review
Serious adverse events at longest · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher serious adverse events (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review